Neurogene (NGNE) Asset Writedowns and Impairment (2023 - 2025)

Neurogene (NGNE) posted Asset Writedowns and Impairment of $120000.0 for Q4 2025, up 31.87% on a QoQ basis from $91000.0 in Q1 2024.

Neurogene (NGNE) Asset Writedowns and Impairment (2023 - 2025) Analysis & Trends

Neurogene's Asset Writedowns and Impairment history runs 3 years deep, the most recent figure standing at $120000.0 for Q4 2025.

Quarterly Asset Writedowns and Impairment changed N/A year-over-year to $120000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $120000.0 (up 31.87% YoY) and the FY2025 annual result came in at $120000.0, up 31.87% from the prior year.
Asset Writedowns and Impairment was $120000.0 for Q4 2025 at Neurogene, up from $91000.0 in the prior quarter.
Across five years, Asset Writedowns and Impairment topped out at $120000.0 in Q4 2025 and bottomed at $91000.0 in Q1 2024.
A 3-year average of $103666.7 and a median of $100000.0 in 2023 frame the typical range for Asset Writedowns and Impairment.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	66,741.39 Bn	66,741.11 Bn	-
2	Nanobiotix	1,912.31 Bn	1,912.25 Bn	-
3	Akari Therapeutics	1,009.43 Bn	1,009.43 Bn	-
4	BeOne Medicines	467.15 Bn	462.36 Bn	1.35 Bn
5	Vertex Pharmaceuticals	123.00 Bn	115.76 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	70.22 Bn	61.47 Bn	3.31 Bn
7	Belite Bio	62.93 Bn	62.93 Bn	-
8	Argenx Se	55.76 Bn	50.57 Bn	1.41 Bn
9	Alnylam Pharmaceuticals	37.70 Bn	34.69 Bn	959.66 Mn
10	Neurogene	761.96 Mn	761.96 Mn	-

Download Data